



Pfizer Limited

The Capital, 1802 / 1901,
Plot No. C - 70, G Block, Bandra Kurla Complex,
Bandra (East), Mumbai 400 051.
Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

July 15, 2019

The Corporate Relationship Dept.
BSE Limited
1st Floor, P.J.Towers
Dalal Street, Fort
Mumbai - 400 001
Scrip Code: 500680

Manager, Listing Dept.
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
Symbol: PFIZER

Dear Sirs,

Sub: Quarterly Compliance Report on Corporate Governance – Regulation 27(2) of the SEBI (LODR) Regulations, 2015

In compliance with Regulation 27(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we submit herewith the Quarterly Compliance Report on Corporate Governance for the quarter ended June 30, 2019.

Kindly take the above on record.

Thanking you,

Yours truly,

For Pfizer Limited

Prajeet Nair
Company Secretary


Encl: A/a

Quarterly Compliance Report on Corporate Governance

Name of the Company: Pfizer Limited

Quarter Ending on : June 30, 2019


I. Composition of the Board of Directors										
Title (Mr. / Ms.)	Name of the Director	PAN ⁵ , DIN and Date of Birth (DD- MM-YYYY)	Category (Chairperson / Executive / Non- Executive / Independent / Nominee) ⁶	Initial Date of Appointment	Date of Appointment in the current term / cessation	Tenure* (in months)	No. of Directorship in listed entities including Pfizer Limited (Refer Regulation 17(A) of Listing Regulations)	No. of Independent Directorship in listed entities including Pfizer Limited (Refer Regulation 17(A) of Listing Regulations)	Number of memberships in Audit / Stakeholder Committee(s) including Pfizer Limited** (Refer Regulation 26 of Listing Regulations)	No. of post of Chairperson in Audit/Stake holder Committee held in listed entities including Pfizer Limited (Refer Regulation 26 of Listing Regulations)
Mr.	R. A. Shah	ABIPS1839C 00009851 07-07-1931	Chairperson - Independent Director – Non-Executive Director	09-11-1965	10/11/2014	56	8	6	6	3
Mr.	Pradip Shah	AAEPS0592F 00066242 07-01-1953	Independent Director – Non-Executive Director	07-12-1999	10/11/2014	56	7	7	6	1



Title (Mr. / Ms.)	Name of the Director	PAN ^S , DIN and Date of Birth (DD- MM-YYYY)	Category (Chairperson / Executive / Non- Executive / Independent / Nominee) ^{&}	Initial Date of Appointment	Date of Appointment in the current term / cessation	Tenure* (in months)	No. of Directorship in listed entities including Pfizer Limited (Refer Regulation 17(A) of Listing Regulations)	No. of Independent Directorship in listed entities including Pfizer Limited (Refer Regulation 17(A) of Listing Regulations)	Number of memberships in Audit / Stakeholder Committee(s) including Pfizer Limited** (Refer Regulation 26 of Listing Regulations)	No. of post of Chairperson in Audit/Stake holder Committee held in listed entities including Pfizer Limited (Refer Regulation 26 of Listing Regulations)
Mr.	Uday Khanna	AFEPK7061E 00079129 01-12-1949	Independent Director – Non-Executive Director	21-05-2012	10/11/2014	56	5	5	7	3
Mr.	Sunil Lalbhai	AAFPL0691R 00045590 15-03-1960	Independent Director – Non-Executive Director	14/02/2015	14/02/2015	53	5	3	4	1
Ms.	Meena Ganesh	ABPPG1456L 00528252 31-08-1963	Independent Director – Non-Executive Director	08/03/2019	08/03/2019 [%]	4	2	2	0	0
Mr.	S. Sridhar	AAHPS2626R 05162648 21-07-1967	Executive Director	14/05/2013	18/03/2016 [@]	N.A.	1	1	1	0



Title (Mr. / Ms.)	Name of the Director	PAN [§] , DIN and Date of Birth (DD-MM-YYYY)	Category (Chairperson / Executive / Non- Executive / Independent / Nominee) ^{&}	Initial Date of Appointment	Date of Appointment in the current term / cessation	Tenure* (in months)	No. of Directorship in listed entities including Pfizer Limited (Refer Regulation 17(A) of Listing Regulations)	No. of Independent Directorship in listed entities including Pfizer Limited (Refer Regulation 17(A) of Listing Regulations)	Number of memberships in Audit / Stakeholder Committee(s) including Pfizer Limited** (Refer Regulation 26 of Listing Regulations)	No. of post of Chairperson in Audit/Stake holder Committee held in listed entities including Pfizer Limited (Refer Regulation 26 of Listing Regulations)
Mr.	Vivek Dhariwal	ADUPD3317Q 02826679 21-12-1966	Executive Director	21-05-2012	21/05/2017 ⁺⁺	N.A.	1	1	1	0
Mr.	Milind Patil ^{^^}	AAEPP3949B 02546815 01-11-1963	Executive Director	14/11/2018	14/11/2018*	N.A.	1	1	0	0
<p>[§] PAN number of any director would not be displayed on the website of Stock Exchange</p> <p>^{&} Category of directors means executive/non-executive/independent/Nominee. If a director fits into more than one category write all categories separating them with hyphen</p> <p>*To be filled only for Independent Director. Tenure would mean total period from which Independent director is serving on Board of directors of the listed entity in continuity without any cooling off period</p> <p>Notes:</p> <p>[#] Mr. R. A. Shah, Mr. Pradip Shah and Mr. Uday Khanna were appointed with effect from November 10, 2014 for a term of five years.</p> <p>[^] Mr. Sunil Lalbhai was appointed with effect from February 14, 2015 for a term of five years.</p> <p>[@] Mr. S. Sridhar was appointed as the Managing Director of the Company with effect from March 18, 2016 for a period of five years.</p> <p>[%] Ms. Meena Ganesh was appointed with effect from March 8, 2019 for a period of five years.</p> <p>⁺⁺ Mr. Vivek Dhariwal was re-appointed as Whole-time Director for a term of 5 years with effect from May 21, 2017. The original date of appointment of Mr. Vivek Dhariwal as Whole-time Director of the Company was May, 21, 2012.</p> <p>^{^^} Mr. Milind Patil was appointed as Whole Time Director for a term of 5 years with effect from November 14, 2018, subject to the approval of the shareholders at the ensuing Annual General Meeting.</p> <p>^{**} Number of memberships in Audit / Stakeholder Committee(s) includes Number of Chairmanship in Audit / Stakeholder Committee, if any.</p>										



II. Composition of Committees			
Name of Committee	Name of Committee Members	Category (Chairperson/ Executive / Non-Executive / Independent/Nominee) [§]	
1. Audit Committee	<ul style="list-style-type: none"> • Mr. R. A. Shah • Mr. Pradip Shah • Mr. Uday Khanna • Mr. S. Sridhar 	Chairperson – Non-Executive - Independent Non-Executive - Independent Non-Executive – Independent Executive	
2. Nomination & Remuneration Committee	<ul style="list-style-type: none"> • Mr. Pradip Shah • Mr. R. A. Shah • Mr. Uday Khanna 	Chairperson - Non-Executive - Independent Non-Executive - Independent Non-Executive – Independent	
3. Risk Management Committee	<ul style="list-style-type: none"> • Mr. Sunil Lalbhai • Mr. Meena Ganesh • Mr. S. Sridhar • Mr. Milind Patil • Mr. Navin Singhania 	Chairperson - Non-Executive - Independent Non-Executive - Independent Executive Executive Employee – Business Technology Lead	
4. Stakeholders Relationship Committee	<ul style="list-style-type: none"> • Mr. Uday Khanna • Mr. Sunil Lalbhai • Mr. Vivek Dhariwal 	Chairperson - Non-Executive - Independent Non-Executive - Independent Executive	
5. Corporate Social Responsibility Committee	<ul style="list-style-type: none"> • Mr. Pradip Shah • Mr. S. Sridhar • Mr. Milind Patil • Mr. Vivek Dhariwal 	Chairperson - Non-Executive - Independent Executive Executive Executive	
[§] Category of directors means executive/non-executive/independent/Nominee. If a director fits into more than one category write all categories separating them with hyphen.			
III. Meeting of Board of Directors			
Date(s) of Meeting (if any) in the previous quarter	Date(s) of Meeting (if any) in the relevant quarter	Maximum gap between any two consecutive (in number of days)	
March 8, 2019	May 28, 2019	80 days	
IV. Meeting of Committees			
Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (details)	Date(s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive number of days*
Audit Committee – May 28, 2019	Yes (100% quorum)	March 8, 2019	80 days
* This information has to be mandatorily be given for audit committee, for rest of the committees giving this information is optional.			



V. Related Party Transactions*	
Subject	Compliance Status (Yes/No/NA) <small>refer note below</small>
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	Yes
Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	Yes
*Details of material transactions with related parties is enclosed as Annexure 1	
Note :	
1. In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.	
2. If status is "No" details of non-compliance may be given here.	

VI. Affirmations
1. The composition of the Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
2. The composition of the following committees is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015
a. Audit Committee
b. Nomination and Remuneration Committee
c. Stakeholders Relationship Committee
d. Risk Management Committee applicable to top 500 Companies
3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
5. The report submitted in the previous quarter has been placed before Board of Directors. This report will be placed before the ensuing meeting of the Board of Directors.

For Pfizer Limited

Prajeet Nair
Company Secretary



Date: July 15, 2019

Place: Mumbai

Encl: A/a

ANNEXURE I
DETAILS OF MATERIAL RELATED PARTY TRANSACTIONS

Particulars	Details
Name of the Related Party	1. Pfizer Innovative Supply Point Intl BVBA, Belgium 2. Pfizer Service Company BVBA, Belgium
Relation with the Company	The Company and the related parties are indirect subsidiaries of Pfizer Inc., USA.
Nature / Description of Transactions	Import of active pharmaceutical ingredients, raw materials and finished products on arm's length basis and in ordinary course of business
Amount of Transactions for the quarter ended March 31, 2019	1. Pfizer Innovative Supply Point Intl BVBA, Belgium – 43.54 crore 2. Pfizer Service Company BVBA, Belgium – 45.71 crore
Period	April 1, 2019 – June 30, 2019

For Pfizer Limited

Prajeet Nair
Company Secretary



Date: July 15, 2019
Place: Mumbai